217 related articles for article (PubMed ID: 24552155)
1. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus.
Seino Y; Inagaki N; Miyahara H; Okuda I; Bush M; Ye J; Holland MC; Johnson S; Lewis E; Nakajima H
Curr Med Res Opin; 2014 Jun; 30(6):1095-106. PubMed ID: 24552155
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
Shaddinger BC; Soffer J; Vlasakakis G; Shabbout M; Weston C; Nino A
Diabetes Res Clin Pract; 2019 Jun; 152():125-134. PubMed ID: 31004676
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
[TBL] [Abstract][Full Text] [Related]
7. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
Rosenstock J; Reusch J; Bush M; Yang F; Stewart M;
Diabetes Care; 2009 Oct; 32(10):1880-6. PubMed ID: 19592625
[TBL] [Abstract][Full Text] [Related]
8. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
Okuda I; Wilson TH; Yue L; Nakajima H; Carr MC; Tsuboi M; Nino A; Seino Y
Curr Med Res Opin; 2017 Mar; 33(3):431-438. PubMed ID: 27852119
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
10. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
11. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
12. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
[TBL] [Abstract][Full Text] [Related]
13. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial.
Rosenstock J; Nino A; Soffer J; Erskine L; Acusta A; Dole J; Carr MC; Mallory J; Home P
Diabetes Care; 2020 Oct; 43(10):2509-2518. PubMed ID: 32694215
[TBL] [Abstract][Full Text] [Related]
14. Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.
Nino A; Okuda I; Wilson TH; Yue L; Nakajima H; Tsuboi M; Carr MC; Seino Y
J Diabetes Investig; 2017 Sep; 9(3):558-66. PubMed ID: 28921915
[TBL] [Abstract][Full Text] [Related]
15. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Davidson JA; Jones-Leone A; Wilson TH; Nino A; Forero-Schwanhaeuser S; Reinhardt RR
Postgrad Med; 2017 Nov; 129(8):849-857. PubMed ID: 29083275
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes.
Matthews JE; Stewart MW; De Boever EH; Dobbins RL; Hodge RJ; Walker SE; Holland MC; Bush MA;
J Clin Endocrinol Metab; 2008 Dec; 93(12):4810-7. PubMed ID: 18812476
[TBL] [Abstract][Full Text] [Related]
17. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
Weissman PN; Carr MC; Ye J; Cirkel DT; Stewart M; Perry C; Pratley R
Diabetologia; 2014 Dec; 57(12):2475-84. PubMed ID: 25208756
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
[TBL] [Abstract][Full Text] [Related]
19. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Pratley RE; Nauck MA; Barnett AH; Feinglos MN; Ovalle F; Harman-Boehm I; Ye J; Scott R; Johnson S; Stewart M; Rosenstock J;
Lancet Diabetes Endocrinol; 2014 Apr; 2(4):289-297. PubMed ID: 24703047
[TBL] [Abstract][Full Text] [Related]
20. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]